Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 5Neoplasms 5Carcinoid Tumor 5Gastro-enteropancreatic neuroendocrine tumor 3Diarrhea 3Carcinoma 3Acromegaly 3Colorectal Neoplasms 2Thymoma 1Rectal Neoplasms 1Pituitary Neoplasms 1Peritoneal Neoplasms 1Neoplasm Metastasis 1Malignant Carcinoid Syndrome 1Intestinal Obstruction 1Disease 1Colonic Neoplasms 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1Adenoma, Islet Cell 1

Interventions

Temozolomide 29Bevacizumab 14Radiotherapy 12Trastuzumab 10Lomustine 9Capecitabine 8paclitaxel-Angiopep-2 conjugate 6Nivolumab 6pembrolizumab 5dabrafenib 5abemaciclib 5Radiation 5icotinib 4Surgical Procedures, Operative 4Paclitaxel 4Lapatinib 4Irinotecan 4Flucytosine 4Dianhydrogalactitol 4Corticotropin-Releasing Hormone 4Chlorotoxin 4Carboplatin 4vocimagene amiretrorepvec 3verubulin 3tucatinib 3osimertinib 3motexafin gadolinium 3XL647 3Spermine Synthase 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Brain Neoplasms × Octreotide × Clear all
NCT00376064 2017-03-06

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Novartis

Phase 4 Completed
20 enrolled
CNSEndocrine

Acromegaly, Brain Neoplasms, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡